Clinical trials: Neurocognitive Disorders, Mild
Alzheimer Disease
Study of BHV-4157 in Alzheimer's Disease
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, were administered orally once daily.
- Trial name
- T2 Protect AD (NCT03605667)
- Testing
- troriluzole
- Where
- 44 sites in United States
- Volunteers
- 350 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Alzheimer Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
- Trial name
- NCT05575076
- Testing
- Simufilam
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 1,081 people
- Sponsor
- Cassava Sciences, Inc.
Dementia, Mild Cognitive Impairment
Patient Priorities Care Among Persons Living With Mild Cognitive Impairment and Dementia
The goal of this pragmatic, embedded clinical trial is to analyze the implementation of Patient Priorities Care in primary care and geriatrics clinics with patients living with dementia or mild cognitive impairment.
- Trial name
- IN-TX-PPC (NCT06001775)
- Testing
- Patient Priorities Care
- Where
- 3 sites in United States
- Volunteers
- 178 people
- Sponsor
- Indiana University
Alzheimer's Disease
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
- Trial name
- NCT02585934
- Testing
- RVT-101
- Where
- 197 sites in United States, Argentina and 17 more
- Volunteers
- 1,315 people
- Sponsor
- Axovant Sciences Ltd.
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Cognitive Dysfunction, Mild Cognitive Impairment
Development and Evaluation of Virtual Reality Experiences for Cognitive Stimulation at the Sociosanitary Center El Carme
The goal of this clinical trial is to test a virtual reality (VR)-based program designed for cognitive stimulation in individuals attending the conventional cognitive rehabilitation program at the Day Hospital of CSSC (Centro…
- Trial name
- RTCSSC (NCT06155721)
- Testing
- Virtual Reality Cognitive Stimulation Program
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Badalona Serveis Assistencials
Mild Cognitive Impairment, Memory Disorders
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment
The purpose of this study is to evaluate if systematic cognitive training can improve cognitive performance in participants (55 and older) with memory loss.
- Conditions
- Mild Cognitive Impairment, Memory Disorders, Memory Impairment, Cognitive Impairment
- Trial name
- CogTraining (NCT03205709)
- Testing
- Computerized Cognitive Training, Crossword Puzzles
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer's Disease
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories…
- Trial name
- NCT02079909
- Testing
- T-817MA-H, T-817MA-L
- Where
- 50 sites in United States
- Volunteers
- 482 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-2 (NCT00348309)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Donepezil
- Where
- 249 sites in United States, Argentina and 17 more
- Volunteers
- 1,496 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Cognitive Decline in Non-demented PD
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
- Trial name
- NCT01340885
- Testing
- Strattera, Exelon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Oregon Health and Science University
Mild Cognitive Impairment
Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)
Nearly 1 in 10 older Americans have dementia, which is a devastating condition that leads to a progressive loss of independence and functional status.
- Trial name
- MCI PLIE (NCT03526146)
- Testing
- Behavioral: Preventing Loss of Independence through Exercise (PLIE)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of California, San Francisco
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind…
- Trial name
- NCT01238991
- Testing
- ACC-001
- Where
- 11 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Pfizer
Mild Cognitive Impairment
Home-Based Dual-Task Training for Older Adults
This project is focused on conducting a home-based, thinking while moving exercise intervention for adults 65 years or older, who have mild cognitive impairment, that will integrate several effective training modalities including…
- Trial name
- NCT05108246
- Testing
- Dual-Task Exercise Training
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- State University of New York at Buffalo
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
A Scalable Model for Promoting Functioning and Well-Being Among Older Adults With Mild Cognitive Impairment Via Meaningful Social Interactions: Project SPEAK!
The goal of this study is to refine and test a strategy for engaging older adults with symptoms of SCD/MCI (subjective cognitive decline/mild cognitive impairment) as volunteers to help English language learners (ELLs) who live…
- Trial name
- NCT04717479
- Testing
- Intervention (videoconferencing)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Dementia, Alzheimer's Disease
Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia
The purpose of this study is to examine the effects of supplementing Magnesium L-Threonate in people with mild to moderate dementia.
- Trial name
- NCT02210286
- Testing
- Magtein
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University